SaniMed Science Group partners with early-stage MedTech startups, providing investment, consulting, and financial support to accelerate growth. With expertise in regulatory processes and market strategy, SaniMed guides companies from concept to FDA approval and launch.

SaniMed Bridge Fund

The SaniMed Bridge Fund, managed by SaniMed Science Group, invests in early-stage innovative projects in MedTech, BioTech, TechBio, Digital Health, and AI healthcare fields. By rigorously assessing market potential and asset valuations, the fund supports entrepreneurial teams with strategic guidance, clear development paths, and optimized investment planning. Leveraging deep industry expertise and a network of world-class institutions, the fund minimizes investment risks, enhances capital efficiency, and maximizes returns, accelerating medical technology innovation.

PROJECTS

Name: SaniMed Science Group
Address: 7505 Fannin Street, Houston, TX, 77054, US
Telephone: 1-832-875-1816

INVESTMENT

TomoWave Medical Group

TomoWave Medical Group is dedicated to advancing and applying cutting-edge 3D/4D Photoacoustic Tomography (PAT) technology. This innovative technology enables structural, functional, and molecular imaging through its exceptional resolution, contrast, and sensitivity. It facilitates real-time, image-guided animal experiments and enables non-invasive, synchronous image-guided biopsies and surgeries. As a leader in the research, development, and production of photoacoustic tomography imaging equipment, TomoWave has successfully launched two pioneering product lines: the Preclinical Animal Photoacoustic Imaging System and the Clinical Photoacoustic Diagnostic System. Notably, the Preclinical Animal Photoacoustic Imaging System has achieved significant commercial success, with sales exceeding 3.5 million USD.

SaniMed Science Group offers specialized consulting services tailored for early-stage MedTech innovators. Our expertise spans regulatory strategy, market readiness, and financial planning, guiding companies from initial concept through FDA approval and beyond. We provide key services including valuation, compliance advisory, and strategic partnership development, helping startups streamline approvals, secure essential funding, and successfully launch in the healthcare market.

Projects

Torskal: Pioneering Green Nanomedicine for Cancer Therapy

Torskal is a French biotech company pioneering non-ionizing plasmonic photothermal therapy (PTT) for oncology. Its lead program, TSK-001, targets nodular basal-cell carcinoma (BCC) using eco-friendly, plant-derived gold nanoparticles activated by near-infrared light. This method destroys cancer cells non-invasively and precisely, offering a safer alternative to traditional therapies. Torskal stands out for its commitment to green nanotechnology, enhancing biocompatibility and sustainability. Led by Dr. Anne-Laure Morel, the company collaborates with top clinical and academic partners and is preparing for Phase 1–2 clinical trials to assess TSK-001’s safety and efficacy. Read More